Fertility and Sterility
Volume 93, Issue 1 , Pages 184-191 , 1 January 2010

Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy

Presented at the Endocrine Society of Australia National Meeting, Christchurch, New Zealand, September 2–5, 2007, and the American Endocrine Society Annual Meeting, San Francisco, California, June 15–18, 2008.

  • Helena J. Teede, Ph.D.

      Affiliations

    • The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Monash University, Melbourne, Victoria, Australia
    • Diabetes Unit, Southern Health, Melbourne, Victoria, Australia
    • ,
  • Caroline Meyer, Ph.D.

      Affiliations

    • Diabetes Unit, Southern Health, Melbourne, Victoria, Australia
    • ,
  • Samantha K. Hutchison, M.B., B.S.

      Affiliations

    • The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Monash University, Melbourne, Victoria, Australia
    • ,
  • Sophia Zoungas, Ph.D.

      Affiliations

    • The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Monash University, Melbourne, Victoria, Australia
    • Diabetes Unit, Southern Health, Melbourne, Victoria, Australia
    • ,
  • Barry P. McGrath, M.D.

      Affiliations

    • Department of Vascular Sciences and Medicine, Centre for Vascular Health, Monash University, Clayton, Victoria, Australia
    • ,
  • Lisa J. Moran, Ph.D.

      Affiliations

    • The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Monash University, Melbourne, Victoria, Australia
    • Corresponding Author InformationReprint requests: Lisa J. Moran, Ph.D., The Jean Hailes Foundation for Women's Health, Monash Institute of Health Services Research, Locked bag 29, Monash Medical Centre, 246 Clayton Rd., Clayton, Victoria 3168, Australia (FAX: 61-03-9594-7554).

Received 3 April 2008 ,Revised 5 September 2008 ,Accepted 6 September 2008.

References 

  1. Teede H, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18:273–279
  2. Norman RJ, Masters SC, Hague W, Beng C, Pannall P, Wang JX. Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertil Steril. 1995;63:329–335
  3. Lakhani K, Prelevic GM, Seifalian AM, Atiomo WU, Hardiman P. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J Obstet Gynaecol. 2004;24:613–621
  4. Deanfield J, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285–1295
  5. Jansson P-A. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med. 2007;262:173–183
  6. Gokce N, Keaney JF, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002;105:1567–1572
  7. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004;109:1343–1348
  8. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241–2247
  9. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. [see comment] Lancet. 2001;358:2127–2128
  10. Meyer C, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4630–4635
  11. Carmassi F, De Negri F, Fioriti R, De Giorgi A, Giannarelli C, Fruzzetti F, et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res. 2005;116:207–214
  12. Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis. 2008;196:958–965
  13. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal SA, et al. Asymmetric dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab. 2008;93:82–90
  14. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:742–746
  15. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610
  16. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005;90:5711–5716
  17. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004;89:5592–5596
  18. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152:749–756
  19. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. Circulation. 2000;101:676–681
  20. Cardillo C, Nambi SS, Kilcoyne CM, Choucair WK, Katz A, Quon MJ, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation. 1999;100:820–825
  21. Orio F, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab. 2005;90:6072–6076
  22. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997;46:454–457
  23. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care. 2007;30:471–478
  24. Zawdaki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens J,  Haseltine F,  Marrian G editor. Polycystic ovary syndrome current issues in endocrinology and metabolism. Vol. 4:Boston: Blackwell Scientific; 1992;p. 377–384
  25. Teede HJ, Dalais FS, Kotsopoulos D, McGrath BP, Malan E, Gan TE, et al. Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women. J Clin Endocrinol Metab. 2005;90:1936–1941
  26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  27. Wolever TM, Jenkins DJ, Jenkins AL, Josse RG. The glycemic index: methodology and clinical implications. Am J Clin Nutr. 1991;54:846–854
  28. Liang YL, Teede H, Kotsopoulos D, Shiel L, Cameron JD, Dart AM, et al. Non-invasive measurements of arterial structure and function: repeatability, interrelationships and trial sample size. Clin Sci. 1998;95:669–679
  29. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol–cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85:3161–3168
  30. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006;21:1426–1431
  31. van Rooijen M, Hansson LO, Frostegard J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost. 2006;4:77–82
  32. Teede HJ. Sex hormones and the cardiovascular system: effects on arterial function in women. Clin Exp Pharmacol Physiol. 2007;34:672–676
  33. Lowenstein L, Damti A, Pillar G, Shott S, Blumenfeld Z. Evaluation of endothelial function in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007;134:208–212
  34. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55:496–505
  35. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine–dependent methyltransferases. Circ Res. 2000;87:99–105
  36. Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation. 2003;108:1575–1580
  37. Verhoeven MO, Hemelaar M, van der Mooren MJ, Kenemans P, Teerlink T. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. J Intern Med. 2006;259:199–208
  38. Banfi C, Eriksson P, Giandomenico G, Mussoni L, Sironi L, Hamsten A, et al. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes. 2001;50:1522–1530
  39. Kooistra T, Bosma PJ, Tons HA, van den Berg AP, Meyer P, Princen HM. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989;62:723–728
  40. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells. Diabetes. 1992;41:890–895
  41. Teede HJ, McGrath BP, Turner A, Majewski H. Effects of oral combined hormone replacement therapy on platelet aggregation in postmenopausal women. Clin Sci. 2001;100:207–213
  42. Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI–independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. [see comment] Thromb Haemost. 2000;84:9–14
  43. Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation. 2002;105:304–309
  44. Smith LH, Coats SR, Qin H, Petrie MS, Covington JW, Su M, et al. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. [see comment] Circ Res. 2004;95:269–275
  45. Ter Avest E, Stalenhoef AF, de Graaf J. What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction?. Clin Sci. 2007;112:507–516
  46. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005;16:2456–2461
  47. Ciampelli M, Leoni F, Cucinelli F, Mancuso S, Panunzi S, De Gaetano A, et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab. 2005;90:1398–1406
  48. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001;86:5457–5464
  49. Williams MR, Westerman RA, Kingwell BA, Paige J, Blombery PA, Sudhir K, et al. Variations in endothelial function and arterial compliance during the menstrual cycle. J Clin Endocrinol Metab. 2001;86:5389–5395

 H.J.T. has nothing to disclose. C.M. has nothing to disclose. S.K.H. has nothing to disclose. S.Z. has nothing to disclose. B.P.M. has served on the Cardiovascular Advisory Boards of Boehringer Ingelheim and Solvay Pharmaceuticals. L.J.M. has nothing to disclose.

 This work was an investigator-initiated trial supported by a competitive Cardiovascular Lipid (CVL) Research Grant sponsored by Pfizer Australia and through internal department funds. H.J.T. received a National Health and Medical Research Council Career Development Award. L.J.M. received the Jean Hailes Fellowship.

PII: S0015-0282(08)03932-0

doi: 10.1016/j.fertnstert.2008.09.034

Fertility and Sterility
Volume 93, Issue 1 , Pages 184-191 , 1 January 2010

Article Tools

* Image Usage & Resolution